Literature DB >> 9348185

The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats.

H Dobnig1, R T Turner.   

Abstract

PTH treatment can result in dramatic increases in cancellous bone volume in normal and osteopenic rats. However, this potentially beneficial response is only observed after pulsatile treatment; continuous infusion of PTH leads to hypercalcemia and bone abnormalities. The purpose of these studies was to determine the optimal duration of the PTH pulses. A preliminary study revealed that human PTH-(1-34) (hPTH) is cleared from circulation within 6 h after sc administration of an anabolic dose of the hormone (80 microg/kg). To establish the effects of gradually extending the duration of exposure to hPTH without increasing the daily dose, we programmed implanted Alzet osmotic pumps to deliver the 80 microg/kg x day dose of the hormone during pulses of 1, 2, and 6 h/day, or 40 microg/kg x day continuously. Discontinuous infusion was accomplished by alternate spacing of external tubing with hPTH solution and sesame oil. After 6 days of treatment, we evaluated serum chemistry and bone histomorphometry. As negative and positive controls, groups of rats received pumps that delivered vehicle only and 80 microg/kg x day hPTH by daily sc injection, respectively. Dynamic and static bone histomorphometry revealed that the daily sc injection and 1 h/day infusion dramatically increased osteoblast number and bone formation in the proximal tibial metaphysis, whereas longer infusion resulted in systemic side-effects, including up to a 10% loss in body weight, hypercalcemia, and histological changes in the proximal tibia resembling abnormalities observed in patients with chronic primary hyperparathyroidism, including peritrabecular marrow fibrosis and focal bone resorption. Infusion for as little as 2 h/day resulted in minor weight loss and changes in bone histology that were intermediate between sc and continuous administration. The results demonstrate that the therapeutic interval for hPTH exposure is brief, but that programmed administration of implanted hormone is a feasible alternative to daily injection as a route for administration of the hormone.

Entities:  

Keywords:  NASA Discipline Regulatory Physiology; Non-NASA Center

Mesh:

Substances:

Year:  1997        PMID: 9348185     DOI: 10.1210/endo.138.11.5505

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  84 in total

1.  PTHrP 1-141 and 1-86 increase in vitro bone formation.

Authors:  Blake Eason Hildreth; Jillian L Werbeck; Nandu K Thudi; Xiyun Deng; Thomas J Rosol; Ramiro E Toribio
Journal:  J Surg Res       Date:  2010-03-16       Impact factor: 2.192

Review 2.  Catabolic and anabolic actions of parathyroid hormone on the skeleton.

Authors:  B C Silva; A G Costa; N E Cusano; S Kousteni; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2011-09-23       Impact factor: 4.256

3.  Phospholipase C signaling via the parathyroid hormone (PTH)/PTH-related peptide receptor is essential for normal bone responses to PTH.

Authors:  Jun Guo; Minlin Liu; Dehong Yang; Mary L Bouxsein; Clare C Thomas; Ernestina Schipani; F Richard Bringhurst; Henry M Kronenberg
Journal:  Endocrinology       Date:  2010-05-25       Impact factor: 4.736

Review 4.  Efficacy of parathyroid hormone supplementation on the osseointegration of implants: a systematic review.

Authors:  Fawad Javed; Mohammad D Al Amri; Sergio Varela Kellesarian; Abdulaziz A Al-Kheraif; Fahim Vohra; José Luis Calvo-Guirado; Hans Malmstrom; Georgios E Romanos
Journal:  Clin Oral Investig       Date:  2015-12-22       Impact factor: 3.573

5.  Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.

Authors:  Masaru Shimizu; Eri Joyashiki; Hiroshi Noda; Tomoyuki Watanabe; Makoto Okazaki; Miho Nagayasu; Kenji Adachi; Tatsuya Tamura; John T Potts; Thomas J Gardella; Yoshiki Kawabe
Journal:  J Bone Miner Res       Date:  2016-05-23       Impact factor: 6.741

6.  Long-term stability and in vitro release of hPTH(1-34) from a multi-reservoir array.

Authors:  Elizabeth R Proos; James H Prescott; Mark A Staples
Journal:  Pharm Res       Date:  2008-06       Impact factor: 4.200

7.  Anabolic effect of intermittent PTH(1-34) on the local microenvironment during the late phase of periodontal repair in a rat model of tooth root resorption.

Authors:  S Lossdörfer; F Yildiz; W Götz; Y Kheralla; A Jäger
Journal:  Clin Oral Investig       Date:  2009-03-12       Impact factor: 3.573

Review 8.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

9.  The PTH-Gαs-protein kinase A cascade controls αNAC localization to regulate bone mass.

Authors:  Martin Pellicelli; Julie A Miller; Alice Arabian; Claude Gauthier; Omar Akhouayri; Joy Y Wu; Henry M Kronenberg; René St-Arnaud
Journal:  Mol Cell Biol       Date:  2014-02-18       Impact factor: 4.272

10.  Phalangeal quantitative ultrasound technology and dual energy X-ray densitometry in patients with primary hyperparathyroidism: influence of sex and menopausal status.

Authors:  V Camozzi; F Lumachi; F Mantero; M Piccolo; G Luisetto
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.